- Home
- ILPT vs LYEL Comparison
ILPT vs LYEL Comparison
Compare ILPT & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ILPT | LYEL |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.0M | 556.1M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ILPT | LYEL |
|---|---|---|
| Price | $7.88 | $17.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.05 | ★ $30.60 |
| AVG Volume (30 Days) | ★ 388.2K | 50.9K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ 31.51 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $5.04 | N/A |
| Revenue Next Year | $2.18 | $8,712.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.01 | $0.40 |
| 52 Week High | $8.30 | $45.00 |
Technical Indicators
Market Signals| Indicator | ILPT | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 64.35 | 32.00 |
| Support Level | $5.15 | $17.34 |
| Resistance Level | $8.19 | $19.02 |
| Average True Range (ATR) | 0.40 | 1.35 |
| MACD | -0.02 | -0.29 |
| Stochastic Oscillator | 62.67 | 8.80 |
Price Performance
Historical ComparisonAbout ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.